Orexo Ab · OMXSTO:ORX
Orexo Ab — Investor Presentation (September 2023)
13 slides from Orexo Ab's investor presentation, September 2023
Slide 1: A commercial stage pharma company with an exciting pipeline
1 A commercial stage pharma company with an exciting pipeline Sep. 2023 Orexo supports the UN’s Agenda 2030 with a focus on:
Slide 2: Legal disclaimer
2 Legal disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Or
Slide 3: Orexo – a commercial stage pharmaceutical company with an exciting pipeline
3 Orexo – a commercial stage pharmaceutical company with an exciting pipeline A commercial stage Profitable US commercial New world leading nasal pharmaceutical company operations with a strong delivery technology - with three revenue focus on one of the largest amorphOX® is leading to generating ph
Slide 4: Commercial products and development pipeline
4 Commercial products and development pipeline Approved and/or Launched Product or Project/Indication/Technology Exploratory Preclinical Clinical development phases Registration US EU RoW ZUBSOLV® Opioid Use Disorder / Sublingual platform Commercial products Abstral® Breaktrough Cancer Pain / Sublin
Slide 5: US market: Commercial products targeting a large unmet need
5 US market: Commercial products targeting a large unmet need Fatal overdoses have surged due to synthetic opioids 1 120000 100000 9,200,000 80000 are misusing opioids2 60000 40000 20000 0 5,600,000 2017 2018 2019 2020 2021 Total overdose deaths All opioid overdoses Synthetic opioids eg fentanyl are
Slide 6: Orexo's development pipeline building on the proprietary amorphOX powder technology
6 Orexo´s development pipeline building on the proprietary amorphOX® powder technology Validated in humans Excellent stability Wide applicability ✓ Superior pharmacokinetic ✓ Excellent stability even under ✓ Powder technology that works accelerated conditions and proven with a broad scope of small a
Slide 7: AmorphOX – a versatile, world-class platform for nasal drug delivery
7 AmorphOX® – a versatile, world-class platform for nasal drug delivery Chemical degradation after accelerated stability studies at 40oC/75% RH Apomorphine Cetrorelix Eletriptan Olanzapine Enzyme Loxapine Retained activity after 0.4% after 24 months 0.5% after 6 months 0.5% after 12 months 0.2% afte
Slide 8: Nasal rescue medications targeting large and growing markets
8 Nasal rescue medications targeting large and growing markets • OX124, high-dose rescue medication incl. naloxone, Global overdose rescue Pojected global medication market size annual growth 1 designed to reverse the effect of the most powerful 2022 (USD) 1 synthetic opioids, such as fentanyl. File
Slide 9: Financial overview
orexo Financial overview /, \ " er / «A
Slide 10: Q2 2023 – improved performance on nearly all financial KPIs
10 Q2 2023 – improved performance on nearly all financial KPIs Comments Q2 Income statement Q2 Q2 H1 H1 FY SEK m 2023 2022 2023 2022 2022 Q2 2023 comments Net revenues 158 148 317 307 624 ✓ Net revenues supported by FX tailwinds and slight ZUBSOLV® volume growth of which US Pharma 145 140 286 279 57
Slide 11: Future value drivers
11 Future value drivers
Slide 12: Several significant milestones near term
12 Several significant milestones near term • Corporate EBITDA profitability in sight1 • Increased income from partners • Main current external cost drivers will diminish during H2 2023 and significant reduction in direct expenses for DTx • No new activities driving external expenses to be initiated
Slide 13: Thanks
? www.orexo.com jo * wt =. y . "3 . «= , > \, be “ * ; , x